Caricamento...
Biosimilars: How Can Payers Get Long-Term Savings?
The term ‘biosimilar’ refers to an alternative similar version of an off-patent innovative originator biotechnology product (the ‘reference product’). Several biosimilars have been approved in Europe, and a number of top-selling biological medicines have lost, or will lose, patent protection over th...
Salvato in:
| Pubblicato in: | Pharmacoeconomics |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863918/ https://ncbi.nlm.nih.gov/pubmed/26792791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-015-0380-x |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|